Skip to main content
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1995 Feb;39(2):516–519. doi: 10.1128/aac.39.2.516

Skin uptake, distribution, and elimination of antimony following administration of sodium stibogluconate to patients with cutaneous leishmaniasis.

M al Jaser 1, A el-Yazigi 1, M Kojan 1, S L Croft 1
PMCID: PMC162570  PMID: 7726524

Abstract

We examined in this study the pharmacokinetics of Sb in the affected skin and normal skin of patients treated with sodium stibogluconate for cutaneous leishmaniasis and compared the results with those for the blood. The procedure was fully explained, and a written consent was obtained from each of nine patients. After a dose of sodium stibogluconate equivalent to 600 mg of Sb was administered intramuscularly, small skin biopsies were collected under local anesthesia at different time intervals from the circumferences of the lesions and simultaneously from normal skin. Antimony was measured in these biopsies after suitable ashing and processing by flameless atomic absorption spectrophotometry. The means (with standard errors of the means in parentheses) of the peak concentration, time to peak concentration, area under the curve, half-life, and mean residence time in lesions were 5.02 (1.43) micrograms/g, 2.1 (0.4) h, 32.8 (6.1) micrograms.h/g, 6.88 (0.54) h, and 10.4 (1.2) h, respectively, and those in normal skin were 6.56 (2.01) micrograms/g, 2.6 (0.8) h, 44.0 (15.8) micrograms.h/g, 5.44 (0.83) h, and 8.08 (1.34) h, respectively. There was no significant difference in any of these parameters between lesions and normal skin, whereas the differences in peak concentration, half-life, and mean residence time between lesions and whole blood were significant (P < or = 0.05). The penetration of Sb into skin, either affected or normal, as measured by the skin/blood area under the curve ratio appears to be complete, but the disposition is slow compared with that from the blood.

Full Text

The Full Text of this article is available as a PDF (180.4 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Berman J. D., Gallalee J. F., Gallalee J. V. Pharmacokinetics of pentavalent antimony (Pentostam) in hamsters. Am J Trop Med Hyg. 1988 Jul;39(1):41–45. doi: 10.4269/ajtmh.1988.39.41. [DOI] [PubMed] [Google Scholar]
  2. Carter K. C., Baillie A. J., Alexander J., Dolan T. F. The therapeutic effect of sodium stibogluconate in BALB/c mice infected with Leishmania donovani is organ-dependent. J Pharm Pharmacol. 1988 May;40(5):370–373. doi: 10.1111/j.2042-7158.1988.tb05271.x. [DOI] [PubMed] [Google Scholar]
  3. Chulay J. D., Fleckenstein L., Smith D. H. Pharmacokinetics of antimony during treatment of visceral leishmaniasis with sodium stibogluconate or meglumine antimoniate. Trans R Soc Trop Med Hyg. 1988;82(1):69–72. [PubMed] [Google Scholar]
  4. Collins M., Carter K. C., Baillie A. J. Visceral leishmaniasis in the BALB/c mouse: antimony tissue disposition and parasite suppression after the administration of free stibogluconate. Ann Trop Med Parasitol. 1992 Feb;86(1):35–40. doi: 10.1080/00034983.1992.11812628. [DOI] [PubMed] [Google Scholar]
  5. Dorea J. G., Merchan-Hamann E., Ryan D. E., Holzbecher J. Retention of antimony in skin biopsies of leishmaniasis patients after treatment with N-methylglucamine antimoniate. Clin Chem. 1990 Apr;36(4):680–682. [PubMed] [Google Scholar]
  6. Faris R. M., Jarallah J. S., Khoja T. A., al-Yamani M. J. Intralesional treatment of cutaneous leishmaniasis with sodium stibogluconate antimony. Int J Dermatol. 1993 Aug;32(8):610–612. doi: 10.1111/j.1365-4362.1993.tb05044.x. [DOI] [PubMed] [Google Scholar]
  7. Kellum R. E. Treatment of cutaneous leishmaniasis with an intralesional antimonial drug (Pentostam). J Am Acad Dermatol. 1986 Oct;15(4 Pt 1):620–622. doi: 10.1016/s0190-9622(86)70214-4. [DOI] [PubMed] [Google Scholar]
  8. Rees P. H., Keating M. I., Kager P. A., Hockmeyer W. T. Renal clearance of pentavalent antimony (sodium stibogluconate). Lancet. 1980 Aug 2;2(8188):226–229. doi: 10.1016/s0140-6736(80)90120-8. [DOI] [PubMed] [Google Scholar]
  9. Sharquie K. E., Al-Talib K. K., Chu A. C. Intralesional therapy of cutaneous leishmaniasis with sodium stibogluconate antimony. Br J Dermatol. 1988 Jul;119(1):53–57. doi: 10.1111/j.1365-2133.1988.tb07100.x. [DOI] [PubMed] [Google Scholar]
  10. TUCKMAN E. Treatment of Chinese kala-azar with sodium antimony gluconate. J Trop Med Hyg. 1949 Oct;52(10):199–204. [PubMed] [Google Scholar]
  11. Ward R. J., Black C. D., Watson G. J. Determination of antimony in biological materials by electrothermal atomic absorption spectroscopy. Clin Chim Acta. 1979 Dec 3;99(2):143–152. doi: 10.1016/0009-8981(79)90037-8. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES